Anlotinib suppresses lung adenocarcinoma growth via inhibiting FASN-mediated lipid metabolism.

ABSTRACT:

Background

Anlotinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, has been widely used in advanced lung cancer patients, but the intrinsic mechanism of cancer cell elimination is not fully disclosed. In this study, we reported that anlotinib suppressed lung adenocarcinoma (LUAD) growth through inhibiting fatty acid synthase (FASN)-mediated lipid metabolism.

Methods

To investigate the underlying mechanisms of anlotinib, an A549 cell line-derived xenograft model was constructed and a proteomics technique was employed to screen potential markers. Gas chromatography-mass spectrometry (GC-MS) profiling of medium-long chain fatty acid and neutral lipid droplet fluorescence staining were employed to detect lipid metabolism in cancer cells. Subsequently, the eff

SUBMITTER: Shen J 

PROVIDER: S-EPMC9843377 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature